Burn	O
wound	O
healing	O
and	O
treatment	O
:	O
review	O
and	O
advancements	O

Burns	O
are	O
a	O
prevalent	O
and	O
burdensome	O
critical	O
care	O
problem	O
.	O

The	O
priorities	O
of	O
specialized	O
facilities	O
focus	O
on	O
stabilizing	O
the	O
patient	O
,	O
preventing	O
infection	B-DS
,	O
and	O
optimizing	O
functional	O
recovery	O
.	O

Research	O
on	O
burns	O
has	O
generated	O
sustained	O
interest	O
over	O
the	O
past	O
few	O
decades	O
,	O
and	O
several	O
important	O
advancements	O
have	O
resulted	O
in	O
more	O
effective	O
patient	O
stabilization	O
and	O
decreased	O
mortality	O
,	O
especially	O
among	O
young	O
patients	O
and	O
those	O
with	O
burns	O
of	O
intermediate	O
extent	O
.	O

However	O
,	O
for	O
the	O
intensivist	O
,	O
challenges	O
often	O
exist	O
that	O
complicate	O
patient	O
support	O
and	O
stabilization	O
.	O

Furthermore	O
,	O
burn	O
wounds	O
are	O
complex	O
and	O
can	O
present	O
unique	O
difficulties	O
that	O
require	O
late	O
intervention	O
or	O
life	O
-	O
long	O
rehabilitation	O
.	O

In	O
addition	O
to	O
improvements	O
in	O
patient	O
stabilization	O
and	O
care	O
,	O
research	O
in	O
burn	O
wound	O
care	O
has	O
yielded	O
advancements	O
that	O
will	O
continue	O
to	O
improve	O
functional	O
recovery	O
.	O

This	O
article	O
reviews	O
recent	O
advancements	O
in	O
the	O
care	O
of	O
burn	O
patients	O
with	O
a	O
focus	O
on	O
the	O
pathophysiology	O
and	O
treatment	O
of	O
burn	O
wounds	O
.	O

Introduction	O

Acute	O
thermal	O
injuries	O
requiring	O
medical	O
treatment	O
affect	O
nearly	O
half	O
a	O
million	O
Americans	O
each	O
year	O
,	O
with	O
approximately	O
40	O
,	O
000	O
hospitalizations	O
and	O
3	O
,	O
400	O
deaths	O
annually	O
[	O
1	O
].	O

The	O
survival	O
rate	O
for	O
admitted	O
burn	O
patients	O
has	O
improved	O
consistently	O
over	O
the	O
past	O
four	O
decades	O
[	O
2	O
]	O
and	O
is	O
currently	O
a	O
favorable	O
97	O
%	O
for	O
patients	O
admitted	O
to	O
burn	O
centers	O
[	O
3	O
].	O

This	O
can	O
be	O
largely	O
attributed	O
to	O
national	O
decreases	O
in	O
burn	O
size	O
,	O
improvements	O
in	O
burn	O
critical	O
care	O
,	O
and	O
advancements	O
in	O
burn	O
wound	O
care	O
and	O
treatment	O
that	O
have	O
been	O
driven	O
by	O
research	O
,	O
as	O
reflected	O
in	O
the	O
dramatic	O
increase	O
in	O
burn	O
publications	O
over	O
the	O
last	O
several	O
decades	O
[	O
4	O
,	O
5	O
].	O

Since	O
the	O
first	O
International	O
Congress	O
on	O
Research	O
in	O
Burns	O
over	O
50	O
years	O
ago	O
,	O
progress	O
has	O
been	O
made	O
in	O
a	O
host	O
of	O
areas	O
,	O
and	O
vital	O
improvements	O
in	O
early	O
resuscitation	O
,	O
infection	B-DS
management	O
,	O
wound	O
excision	O
and	O
coverage	O
,	O
and	O
fluid	O
management	O
have	O
helped	O
in	O
the	O
fight	O
against	O
burn	O
mortality	O
[	O
6	O
,	O
7	O
].	O

This	O
review	O
presents	O
an	O
update	O
on	O
the	O
care	O
of	O
burn	O
patients	O
,	O
with	O
special	O
emphasis	O
on	O
the	O
mechanisms	O
underlying	O
burn	O
wound	O
healing	O
and	O
recent	O
advancements	O
in	O
burn	O
wound	O
care	O
.	O

Pathophysiology	O
of	O
burn	O
wounds	O

Thermal	O
burns	O
from	O
dry	O
sources	O
(	O
fire	O
or	O
flame	O
)	O
and	O
wet	O
sources	O
(	O
scalds	O
)	O
account	O
for	O
approximately	O
80	O
%	O
of	O
all	O
reported	O
burns	O
[	O
8	O
]	O
and	O
can	O
be	O
classified	O
based	O
on	O
the	O
depth	O
of	O
burn	O
[	O
9	O
,	O
10	O
].	O

In	O
addition	O
to	O
local	O
injury	O
at	O
the	O
site	O
of	O
burn	O
,	O
severe	O
thermal	O
injury	O
over	O
a	O
large	O
area	O
of	O
the	O
skin	O
,	O
roughly	O
20	O
%	O
total	O
body	O
surface	O
area	O
(	O
TBSA	O
)	O
or	O
greater	O
,	O
results	O
in	O
acute	O
systemic	O
responses	O
collectively	O
known	O
as	O
burn	B-DS
shock	I-DS
[	O
11	O
].	O

Burn	B-DS
shock	I-DS
is	O
characterized	O
by	O
increased	O
capillary	O
permeability	O
,	O
increased	O
hydrostatic	O
pressure	O
across	O
the	O
microvasculature	O
,	O
protein	O
and	O
fluid	O
movement	O
from	O
the	O
intravascular	O
space	O
into	O
the	O
interstitial	O
space	O
,	O
increased	O
systemic	O
vascular	O
resistance	O
,	O
reduced	O
cardiac	O
output	O
,	O
and	O
hypovolemia	O
requiring	O
fluid	O
resuscitation	O
[	O
12	O
].	O

The	O
edema	O
that	O
forms	O
in	O
the	O
interstitial	O
space	O
forms	O
rapidly	O
in	O
the	O
first	O
8	O
h	O
following	O
burn	O
injury	O
,	O
and	O
continues	O
to	O
form	O
more	O
slowly	O
for	O
at	O
least	O
18	O
h	O
[	O
13	O
].	O

Volume	O
requirements	O
for	O
resuscitation	O
can	O
be	O
estimated	O
by	O
the	O
total	O
burn	O
size	O
and	O
the	O
patient	O
’	O
s	O
weight	O
(	O
or	O
body	O
surface	O
area	O
).	O

Additional	O
factors	O
influencing	O
these	O
needs	O
include	O
the	O
presence	O
or	O
absence	O
of	O
inhalation	O
injury	O
,	O
the	O
extent	O
of	O
full	O
-	O
thickness	O
burns	O
,	O
and	O
the	O
time	O
since	O
injury	O
[	O
12	O
].	O

The	O
actual	O
fluid	O
infusion	O
rate	O
is	O
then	O
titrated	O
hourly	O
,	O
based	O
on	O
the	O
adequacy	O
of	O
physiological	O
responses	O
,	O
such	O
as	O
the	O
urine	O
output	O
[	O
14	O
].	O

Following	O
successful	O
resuscitation	O
,	O
patients	O
with	O
larger	O
burns	O
then	O
enter	O
a	O
more	O
prolonged	O
period	O
of	O
hypermetabolism	O
,	O
chronic	O
inflammation	O
,	O
and	O
lean	O
body	O
mass	O
wasting	O
,	O
all	O
of	O
which	O
may	O
impair	O
wound	O
healing	O
[	O
15	O
].	O

Additionally	O
,	O
an	O
increased	O
susceptibility	O
to	O
infection	B-DS
due	O
to	O
altered	O
immune	O
status	O
may	O
lead	O
to	O
sepsis	B-DS
,	O
further	O
exacerbating	O
systemic	O
inflammation	O
[	O
16	O
].	O

Sustained	O
hypermetabolism	O
and	O
inflammation	O
impair	O
wound	O
healing	O
through	O
delayed	O
re	O
-	O
epithelialization	O
[	O
17	O
,	O
18	O
].	O

The	O
extent	O
of	O
inflammation	O
and	O
hypermetabolism	O
is	O
related	O
to	O
the	O
extent	O
[	O
19	O
]	O
and	O
depth	O
of	O
burn	O
,	O
as	O
deeper	O
burns	O
show	O
higher	O
levels	O
of	O
circulating	O
cytokines	B-GP
[	O
20	O
]	O
and	O
a	O
greater	O
hypermetabolic	O
response	O
[	O
21	O
].	O

Similarly	O
,	O
the	O
extent	O
of	O
burn	O
is	O
an	O
efficient	O
predictor	O
of	O
hospital	O
length	O
of	O
stay	O
[	O
19	O
,	O
22	O
]	O
and	O
mortality	O
[	O
19	O
,	O
23	O
].	O

According	O
to	O
one	O
model	O
,	O
the	O
burn	O
wound	O
can	O
be	O
divided	O
into	O
three	O
zones	O
based	O
on	O
the	O
severity	O
of	O
tissue	O
destruction	O
and	O
alterations	O
in	O
blood	O
flow	O
[	O
10	O
,	O
24	O
–	O
26	O
].	O

The	O
central	O
part	O
of	O
the	O
wound	O
,	O
known	O
as	O
the	O
zone	O
of	O
coagulation	O
,	O
is	O
exposed	O
to	O
the	O
greatest	O
amount	O
of	O
heat	O
and	O
suffers	O
the	O
most	O
damage	O
.	O

Proteins	O
denature	O
above	O
41	O
°	O
C	O
(	O
106	O
°	O
F	O
),	O
so	O
excessive	O
heat	O
at	O
the	O
site	O
of	O
injury	O
results	O
in	O
extensive	O
protein	O
denaturation	O
,	O
degradation	O
,	O
and	O
coagulation	O
,	O
leading	O
to	O
tissue	O
necrosis	O
.	O

Around	O
the	O
central	O
zone	O
of	O
coagulation	O
is	O
the	O
zone	O
of	O
stasis	O
,	O
or	O
zone	O
of	O
ischemia	O
,	O
which	O
is	O
characterized	O
by	O
decreased	O
perfusion	O
and	O
potentially	O
salvageable	O
tissue	O
[	O
10	O
].	O

In	O
this	O
zone	O
,	O
hypoxia	O
and	O
ischemia	O
can	O
lead	O
to	O
tissue	O
necrosis	O
within	O
48	O
h	O
of	O
injury	O
in	O
the	O
absence	O
of	O
intervention	O
[	O
27	O
].	O

The	O
mechanisms	O
underlying	O
apoptosis	O
and	O
necrosis	O
in	O
the	O
ischemic	O
zone	O
remain	O
poorly	O
understood	O
,	O
but	O
appear	O
to	O
involve	O
immediate	O
autophagy	O
within	O
the	O
first	O
24	O
h	O
following	O
injury	O
and	O
delayed	O
-	O
onset	O
apoptosis	O
around	O
24	O
to	O
48	O
h	O
postburn	O
[	O
27	O
].	O

Other	O
studies	O
have	O
shown	O
apoptosis	O
to	O
be	O
active	O
as	O
early	O
as	O
30	O
min	O
postburn	O
[	O
28	O
]	O
depending	O
on	O
the	O
intensity	O
of	O
the	O
burn	O
injury	O
[	O
29	O
].	O

Oxidative	O
stress	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
necrosis	O
,	O
as	O
preclinical	O
studies	O
have	O
demonstrated	O
promising	O
reductions	O
in	O
necrosis	O
with	O
systemic	O
antioxidant	O
administration	O
[	O
30	O
].	O

At	O
the	O
outermost	O
regions	O
of	O
the	O
burn	O
wound	O
is	O
the	O
zone	O
of	O
hyperemia	B-DS
that	O
receives	O
increased	O
blood	O
flow	O
via	O
inflammatory	O
vasodilation	O
and	O
will	O
likely	O
recover	O
,	O
barring	O
infection	B-DS
or	O
other	O
injury	O
[	O
25	O
].	O

Although	O
burns	O
are	O
different	O
from	O
other	O
wounds	O
in	O
some	O
respects	O
,	O
such	O
as	O
the	O
degree	O
of	O
systemic	O
inflammation	O
[	O
31	O
],	O
healing	O
of	O
all	O
wounds	O
is	O
a	O
dynamic	O
process	O
with	O
overlapping	O
phases	O
[	O
32	O
]	O
(	O
Table	O
1	O
).	O

The	O
initial	O
inflammatory	O
phase	O
brings	O
neutrophils	O
and	O
monocytes	O
to	O
the	O
site	O
of	O
injury	O
via	O
localized	O
vasodilation	O
and	O
fluid	O
extravasation	O
,	O
thereby	O
initiating	O
an	O
immune	O
response	O
that	O
is	O
later	O
sustained	O
by	O
the	O
recruitment	O
of	O
macrophages	O
by	O
chemokines	B-GP
[	O
31	O
].	O

The	O
inflammatory	O
phase	O
serves	O
not	O
only	O
to	O
prevent	O
infection	B-DS
during	O
healing	O
,	O
but	O
also	O
to	O
degrade	O
necrotic	O
tissue	O
and	O
activate	O
signals	O
required	O
for	O
wound	O
repair	O
[	O
33	O
].	O

Following	O
,	O
and	O
overlapping	O
with	O
the	O
inflammatory	O
response	O
,	O
the	O
proliferative	O
phase	O
is	O
characterized	O
by	O
keratinocyte	O
and	O
fibroblast	O
activation	O
by	O
cytokines	B-GP
and	O
growth	O
factors	O
[	O
34	O
].	O

In	O
this	O
phase	O
,	O
keratinocytes	O
migrate	O
over	O
the	O
wound	O
to	O
assist	O
in	O
closure	O
and	O
restoration	O
of	O
a	O
vascular	O
network	O
,	O
which	O
is	O
a	O
vital	O
step	O
in	O
the	O
wound	O
healing	O
process	O
[	O
35	O
].	O

This	O
network	O
of	O
communication	O
between	O
stromal	O
,	O
endothelial	O
,	O
and	O
immune	O
cells	O
determines	O
the	O
course	O
of	O
healing	O
,	O
including	O
closure	O
and	O
revascularization	O
.	O
Table	O
1Phases	O
of	O
wound	O
healingPhaseCharacteristicsKey	O
playersInflammatoryVasodilationNeutrophilsFluid	O
extravasationMonocytesEdemaMacrophagesProliferativeWound	O
closureKeratinocytesRevascularizationFibroblastsRemodelingWound	O
maturationCollagenScarringElastinFibroblasts	B-GP
/	O
myofibroblasts	O

Overlapping	O
with	O
the	O
proliferative	O
phase	O
,	O
the	O
final	O
phase	O
of	O
healing	O
involves	O
remodeling	O
the	O
wound	O
[	O
36	O
].	O

During	O
the	O
remodeling	O
phase	O
,	O
the	O
wound	O
scar	O
matures	O
[	O
31	O
]	O
as	O
collagen	B-GP
and	O
elastin	B-GP
are	O
deposited	O
and	O
continuously	O
reformed	O
as	O
fibroblasts	O
become	O
myofibroblasts	O
[	O
37	O
].	O

Myofibroblasts	O
adopt	O
a	O
contractile	O
phenotype	O
,	O
and	O
thus	O
are	O
involved	O
in	O
wound	O
contracture	O
[	O
38	O
].	O

The	O
conversion	O
from	O
fibroblasts	O
to	O
myofibroblasts	O
controls	O
a	O
delicate	O
balance	O
between	O
contraction	O
and	O
re	O
-	O
epithelialization	O
that	O
,	O
in	O
part	O
,	O
determines	O
the	O
pliability	O
of	O
the	O
repaired	O
wound	O
[	O
39	O
].	O

In	O
addition	O
to	O
fibroblast	O
conversion	O
,	O
apoptosis	O
of	O
keratinocytes	O
and	O
inflammatory	O
cells	O
are	O
key	O
steps	O
in	O
the	O
termination	O
of	O
wound	O
healing	O
and	O
the	O
overall	O
final	O
appearance	O
of	O
the	O
wound	O
[	O
40	O
].	O

Optimization	O
of	O
burn	O
wound	O
healing	O

Inflammation	O

Inflammation	O
is	O
vital	O
to	O
successful	O
burn	O
wound	O
healing	O
,	O
and	O
inflammatory	O
mediators	O
(	O
cytokines	B-GP
,	O
kinins	B-GP
,	O
lipids	O
,	O
and	O
so	O
forth	O
)	O
provide	O
immune	O
signals	O
to	O
recruit	O
leukocytes	O
and	O
macrophages	O
that	O
initiate	O
the	O
proliferative	O
phase	O
[	O
37	O
].	O

Wound	O
re	O
-	O
epithelialization	O
,	O
or	O
closure	O
,	O
in	O
the	O
proliferative	O
phase	O
via	O
keratinocyte	O
and	O
fibroblast	O
activation	O
,	O
or	O
migration	O
from	O
dedifferentiated	O
hair	O
follicles	O
and	O
other	O
epidermal	O
analogs	O
[	O
41	O
,	O
42	O
],	O
is	O
mediated	O
by	O
cytokines	B-GP
recruited	O
in	O
the	O
inflammatory	O
phase	O
.	O

While	O
this	O
indicates	O
that	O
inflammation	O
is	O
essential	O
for	O
wound	O
healing	O
,	O
aberrant	O
inflammatory	O
pathways	O
have	O
also	O
been	O
linked	O
to	O
hypertrophic	O
scarring	O
,	O
and	O
anti	O
-	O
inflammatory	O
treatments	O
could	O
potentially	O
aggravate	O
symptoms	O
and	O
delay	O
wound	O
healing	O
[	O
40	O
,	O
43	O
,	O
44	O
].	O

Significant	O
edema	O
that	O
is	O
initiated	O
by	O
several	O
factors	O
including	O
vasodilation	O
,	O
extravascular	O
osmotic	O
activity	O
,	O
and	O
increased	O
microvascular	O
permeability	O
often	O
accompanies	O
inflammation	O
[	O
45	O
].	O

Excessive	O
or	O
prolonged	O
edema	O
and	O
inflammation	O
exacerbate	O
pain	O
and	O
impair	O
wound	O
healing	O
[	O
17	O
,	O
18	O
].	O

Interestingly	O
,	O
studies	O
suggest	O
that	O
in	O
the	O
absence	O
of	O
infection	B-DS
,	O
inflammation	O
might	O
not	O
be	O
required	O
for	O
tissue	O
repair	O
[	O
46	O
].	O

Since	O
inflammation	O
can	O
have	O
both	O
beneficial	O
and	O
detrimental	O
effects	O
on	O
burn	O
wound	O
healing	O
,	O
the	O
clinical	O
challenge	O
becomes	O
management	O
,	O
applying	O
therapeutic	O
intervention	O
only	O
when	O
inflammation	O
and	O
edema	O
become	O
excessive	O
.	O

Treatment	O
of	O
inflammation	O
in	O
large	O
burns	O
is	O
difficult	O
,	O
as	O
recently	O
discussed	O
in	O
detail	O
elsewhere	O
[	O
16	O
].	O

Traditional	O
anti	O
-	O
inflammatory	O
treatments	O
that	O
focus	O
on	O
the	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
,	O
such	O
as	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
or	O
glucocorticoids	O
,	O
impair	O
wound	O
healing	O
[	O
47	O
].	O

However	O
,	O
steroid	O
administration	O
has	O
been	O
shown	O
to	O
reduce	O
inflammation	O
,	O
pain	O
,	O
and	O
length	O
of	O
hospital	O
stay	O
in	O
burn	O
patients	O
in	O
several	O
small	O
studies	O
[	O
48	O
,	O
49	O
].	O

Early	O
excision	O
and	O
grafting	O
has	O
become	O
the	O
gold	O
standard	O
for	O
treatment	O
of	O
full	O
and	O
deep	O
partial	O
thickness	O
burns	O
[	O
50	O
,	O
51	O
],	O
in	O
part	O
because	O
early	O
excision	O
helps	O
reduce	O
the	O
risk	O
of	O
infection	B-DS
and	O
scarring	O
[	O
52	O
–	O
54	O
].	O

The	O
timing	O
of	O
debridement	O
coincides	O
with	O
the	O
inflammatory	O
phase	O
of	O
healing	O
,	O
as	O
the	O
burn	O
eschar	O
removed	O
during	O
excision	O
is	O
an	O
inflammatory	O
nidus	O
and	O
a	O
rich	O
pabulum	O
for	O
bacterial	O
proliferation	O
.	O

Nontraditional	O
anti	O
-	O
inflammatory	O
treatments	O
,	O
such	O
as	O
opioids	O
,	O
have	O
gained	O
considerable	O
attention	O
but	O
have	O
yet	O
to	O
translate	O
promising	O
preclinical	O
results	O
into	O
clinical	O
practice	O
for	O
wound	O
healing	O
.	O

While	O
the	O
majority	O
of	O
animal	B-OG
studies	O
have	O
demonstrated	O
consistent	O
anti	O
-	O
inflammatory	O
effects	O
of	O
opioids	O
on	O
peripheral	O
neurons	O
[	O
55	O
],	O
clinical	O
studies	O
have	O
shown	O
little	O
to	O
no	O
effect	O
on	O
inflammation	O
[	O
56	O
].	O

Furthermore	O
,	O
topical	O
morphine	O
delayed	O
the	O
early	O
inflammatory	O
phase	O
and	O
accelerated	O
the	O
later	O
proliferative	O
phase	O
[	O
57	O
,	O
58	O
],	O
which	O
is	O
supported	O
by	O
in	O
vitro	O
studies	O
showing	O
opioid	O
stimulation	O
of	O
keratinocyte	O
migration	O
[	O
59	O
].	O

Large	O
-	O
scale	O
clinical	O
trials	O
evaluating	O
opioid	O
efficacy	O
on	O
wound	O
healing	O
have	O
not	O
yet	O
been	O
conducted	O
[	O
60	O
].	O

Infection	B-DS

The	O
skin	O
functions	O
as	O
a	O
barrier	O
to	O
the	O
external	O
environment	O
to	O
maintain	O
fluid	O
homeostasis	O
and	O
body	O
temperature	O
,	O
while	O
providing	O
sensory	O
information	O
along	O
with	O
metabolic	O
and	O
immunological	O
support	O
.	O

Damage	O
to	O
this	O
barrier	O
following	O
a	O
burn	O
disrupts	O
the	O
innate	O
immune	O
system	O
and	O
increases	O
susceptibility	O
to	O
bacterial	B-DS
infection	I-DS
[	O
61	O
].	O

Burn	O
wound	B-DS
infection	I-DS
was	O
defined	O
in	O
a	O
rat	B-OG
model	O
with	O
Pseudomonas	B-OG
aeruginosa	I-OG
[	O
62	O
,	O
63	O
],	O
in	O
which	O
the	O
following	O
progression	O
was	O
observed	O
:	O
burn	O
wound	O
colonization	O
;	O
invasion	O
into	O
subjacent	O
tissue	O
within	O
5	O
days	O
;	O
destruction	O
of	O
granulation	O
tissue	O
;	O
visceral	O
hematogenous	O
lesions	O
;	O
and	O
leukopenia	B-DS
,	O
hypothermia	O
,	O
and	O
death	O
.	O

Burn	O
patients	O
are	O
at	O
high	O
risk	O
for	O
infection	B-DS
[	O
64	O
],	O
especially	O
drug	O
-	O
resistant	O
infection	B-DS
[	O
65	O
],	O
which	O
often	O
results	O
in	O
significantly	O
longer	O
hospital	O
stays	O
,	O
delayed	O
wound	O
healing	O
,	O
higher	O
costs	O
,	O
and	O
higher	O
mortality	O
[	O
66	O
].	O

Infection	B-DS
can	O
lead	O
to	O
the	O
development	O
of	O
a	O
pronounced	O
immune	O
response	O
,	O
accompanied	O
by	O
sepsis	B-DS
or	O
septic	O
shock	O
,	O
which	O
results	O
in	O
hypotension	O
and	O
impaired	O
perfusion	O
of	O
end	O
organs	O
,	O
including	O
the	O
skin	O
–	O
all	O
processes	O
that	O
delay	O
wound	O
healing	O
.	O

Furthermore	O
,	O
the	O
leading	O
causes	O
of	O
death	O
following	O
a	O
severe	O
burn	O
are	O
sepsis	B-DS
and	O
multiorgan	O
failure	O
[	O
67	O
–	O
69	O
],	O
so	O
prevention	O
and	O
management	O
of	O
infection	B-DS
is	O
a	O
primary	O
concern	O
in	O
the	O
treatment	O
of	O
burn	O
patients	O
.	O

Early	O
and	O
accurate	O
diagnosis	O
of	O
infection	B-DS
is	O
difficult	O
:	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
and	O
the	O
white	O
blood	O
cell	O
count	O
are	O
most	O
often	O
used	O
,	O
since	O
the	O
diagnostic	O
power	O
of	O
procalcitonin	B-GP
is	O
questionable	O
in	O
burns	O
[	O
70	O
].	O

Consensus	O
definitions	O
of	O
sepsis	B-DS
and	O
infection	B-DS
have	O
recently	O
been	O
proposed	O
that	O
are	O
more	O
relevant	O
to	O
the	O
burn	O
population	O
and	O
are	O
often	O
used	O
clinically	O
but	O
still	O
require	O
validation	O
[	O
71	O
].	O

The	O
management	O
of	O
burn	O
wound	B-DS
infections	I-DS
has	O
been	O
extensively	O
reviewed	O
elsewhere	O
[	O
61	O
,	O
64	O
–	O
66	O
,	O
72	O
–	O
77	O
].	O

Since	O
the	O
adoption	O
of	O
topical	O
antibiotics	O
,	O
such	O
as	O
mafenide	O
in	O
the	O
1960s	O
and	O
silver	O
sulfadiazine	O
in	O
the	O
1970s	O
,	O
and	O
of	O
early	O
excision	O
and	O
grafting	O
in	O
the	O
1970s	O
and	O
thereafter	O
,	O
systemic	B-DS
infections	I-DS
and	O
mortality	O
have	O
consistently	O
decreased	O
[	O
68	O
,	O
72	O
,	O
78	O
].	O

However	O
,	O
Gram	O
-	O
positive	O
and	O
Gram	B-DS
-	I-DS
negative	I-DS
bacterial	I-DS
infections	I-DS
still	O
remain	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
mortality	O
following	O
burn	O
injury	O
[	O
73	O
].	O

Bacterial	O
cultures	O
can	O
aid	O
in	O
the	O
selection	O
of	O
an	O
appropriate	O
antibiotic	O
,	O
especially	O
in	O
cases	O
of	O
bacterial	O
drug	O
resistance	O
,	O
but	O
altered	O
pharmacokinetic	O
parameters	O
in	O
burn	O
patients	O
must	O
be	O
considered	O
and	O
dosing	O
should	O
be	O
adjusted	O
accordingly	O
to	O
maximize	O
antibiotic	O
efficacy	O
[	O
79	O
].	O

Importantly	O
,	O
effective	O
topical	O
antimicrobials	O
do	O
not	O
exist	O
for	O
invasive	O
fungal	B-DS
infections	I-DS
,	O
and	O
fungal	B-DS
wound	I-DS
infections	I-DS
are	O
associated	O
with	O
greater	O
mortality	O
rates	O
in	O
large	O
burns	O
(>	O
30	O
%	O
TBSA	O
)	O
[	O
80	O
].	O

Owing	O
to	O
high	O
lethality	O
,	O
suspicion	O
of	O
an	O
invasive	O
burn	O
wound	B-DS
infection	I-DS
mandates	O
rapid	O
diagnosis	O
,	O
often	O
by	O
histopathology	O
,	O
and	O
excision	O
or	O
re	O
-	O
excision	O
of	O
the	O
wound	O
.	O

Nutrition	O

Sustained	O
hypermetabolism	O
,	O
hormone	O
elevations	O
,	O
and	O
muscle	O
wasting	O
following	O
severe	O
burn	O
injury	O
all	O
contribute	O
to	O
the	O
clinical	O
outcome	O
,	O
with	O
magnitude	O
and	O
duration	O
that	O
are	O
unique	O
to	O
burns	O
[	O
81	O
,	O
82	O
].	O

Accordingly	O
,	O
reducing	O
the	O
impact	O
of	O
a	O
hypermetabolic	O
state	O
and	O
providing	O
adequate	O
nutrition	O
are	O
key	O
factors	O
that	O
affect	O
burn	O
wound	O
healing	O
and	O
recovery	O
[	O
83	O
],	O
as	O
has	O
been	O
reviewed	O
elsewhere	O
[	O
84	O
].	O

There	O
is	O
a	O
difficult	O
balance	O
between	O
the	O
additional	O
caloric	O
needs	O
to	O
meet	O
the	O
demand	O
from	O
hypermetabolism	O
and	O
the	O
consequences	O
of	O
nutrient	O
overconsumption	O
.	O

Nutritional	O
support	O
following	O
a	O
burn	O
injury	O
is	O
a	O
complex	O
issue	O
.	O

For	O
example	O
,	O
early	O
excision	O
and	O
aggressive	O
feeding	O
in	O
children	O
does	O
not	O
diminish	O
energy	O
expenditure	O
but	O
is	O
associated	O
with	O
decreased	O
muscle	O
protein	O
catabolism	O
,	O
a	O
decreased	O
rate	O
of	O
burn	O
sepsis	B-DS
,	O
and	O
significantly	O
lower	O
bacterial	O
counts	O
from	O
excised	O
tissue	O
[	O
85	O
].	O

In	O
adults	O
,	O
early	O
nutritional	O
support	O
is	O
correlated	O
with	O
shorter	O
stays	O
,	O
accelerated	O
wound	O
healing	O
,	O
and	O
decreased	O
risk	O
of	O
infection	B-DS
[	O
86	O
].	O

Several	O
nutritional	O
factors	O
must	O
be	O
considered	O
.	O

For	O
example	O
,	O
excess	O
carbohydrate	O
consumption	O
may	O
lead	O
to	O
hyperglycemia	B-DS
[	O
87	O
]	O
that	O
can	O
exacerbate	O
systemic	O
inflammation	O
and	O
muscle	O
degradation	O
[	O
88	O
,	O
89	O
].	O

Furthermore	O
,	O
excess	O
fat	O
consumption	O
may	O
exaggerate	O
the	O
immunosuppressed	O
state	O
[	O
90	O
];	O
and	O
since	O
major	O
burn	O
injuries	O
may	O
also	O
result	O
in	O
immunosuppression	O
[	O
91	O
],	O
this	O
exaggeration	O
may	O
increase	O
the	O
risk	O
for	O
infection	B-DS
and	O
sepsis	B-DS
.	O

Carbohydrate	O
and	O
fat	O
intake	O
must	O
therefore	O
be	O
closely	O
monitored	O
in	O
burn	O
patients	O
.	O

Guidelines	O
for	O
nutritional	O
support	O
of	O
burn	O
patients	O
vary	O
,	O
but	O
consensus	O
recommendations	O
have	O
been	O
given	O
by	O
the	O
American	O
Burn	O
Association	O
and	O
the	O
American	O
Society	O
for	O
Parenteral	O
and	O
Enteral	O
Nutrition	O
for	O
carbohydrates	O
,	O
proteins	O
,	O
and	O
fats	O
[	O
84	O
].	O

In	O
addition	O
to	O
support	O
with	O
amino	O
acids	O
and	O
vitamins	O
[	O
84	O
],	O
administration	O
of	O
insulin	O
has	O
been	O
shown	O
to	O
decrease	O
healing	O
time	O
by	O
reducing	O
protein	O
catabolism	O
and	O
increasing	O
skeletal	O
muscle	O
protein	O
synthesis	O
[	O
92	O
–	O
96	O
].	O

More	O
research	O
is	O
needed	O
to	O
optimize	O
insulin	O
delivery	O
,	O
as	O
many	O
recombinant	O
growth	O
factors	O
,	O
such	O
as	O
epidermal	B-GP
growth	I-GP
factor	I-GP
and	O
transforming	B-GP
growth	I-GP
factor	I-GP
,	O
are	O
often	O
cost	O
prohibitive	O
[	O
93	O
].	O

Other	O
anabolic	O
agents	O
,	O
such	O
as	O
oxandrolone	O
,	O
have	O
been	O
shown	O
to	O
increase	O
lean	O
body	O
mass	O
recovery	O
,	O
decrease	O
length	O
of	O
stay	O
,	O
and	O
improve	O
overall	O
outcomes	O
,	O
including	O
wound	O
healing	O
[	O
97	O
–	O
100	O
].	O

Additionally	O
,	O
while	O
conventional	O
theory	O
suggests	O
that	O
hemoglobin	B-GP
levels	O
must	O
be	O
maintained	O
above	O
10	O
g	O
/	O
dl	O
to	O
promote	O
wound	O
healing	O
[	O
101	O
],	O
preliminary	O
evidence	O
suggests	O
that	O
mild	O
to	O
moderate	O
anemia	B-DS
has	O
no	O
effect	O
on	O
graft	O
success	O
if	O
perfusion	O
is	O
maintained	O
with	O
proper	O
circulatory	O
volume	O
[	O
102	O
].	O

The	O
results	O
of	O
a	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
trial	O
(	O
ClinicalTrials	O
.	O
gov	O
NCT01079247	O
)	O
comparing	O
blood	O
transfusion	O
with	O
lower	O
volumes	O
(	O
target	O
hemoglobin	B-GP
of	O
7	O
to	O
8	O
g	O
/	O
dl	O
)	O
and	O
conventional	O
volumes	O
(	O
target	O
hemoglobin	B-GP
>	O
10	O
g	O
/	O
dl	O
)	O
for	O
a	O
large	O
cohort	O
of	O
patients	O
are	O
expected	O
soon	O
and	O
will	O
allow	O
for	O
more	O
definitive	O
clinical	O
guidelines	O
on	O
blood	O
transfusion	O
volumes	O
.	O

Resuscitation	O

Severe	O
thermal	O
injuries	O
over	O
a	O
large	O
area	O
of	O
the	O
skin	O
(>	O
20	O
%	O
TBSA	O
)	O
require	O
fluid	O
resuscitation	O
for	O
stabilization	O
.	O

Although	O
volume	O
guidelines	O
and	O
fluid	O
compositions	O
vary	O
widely	O
between	O
centers	O
,	O
the	O
goal	O
of	O
fluid	O
resuscitation	O
is	O
to	O
maintain	O
organ	O
perfusion	O
with	O
the	O
least	O
amount	O
of	O
fluid	O
necessary	O
[	O
12	O
].	O

Common	O
traditional	O
resuscitation	O
formulas	O
,	O
such	O
as	O
the	O
modified	O
Brooke	O
,	O
and	O
Parkland	O
formulas	O
,	O
employ	O
crystalloids	O
such	O
as	O
lactated	O
Ringer	O
’	O
s	O
that	O
contain	O
sodium	O
,	O
chloride	O
,	O
calcium	O
,	O
potassium	O
,	O
and	O
lactate	O
.	O

During	O
large	O
-	O
volume	O
resuscitations	O
,	O
the	O
addition	O
of	O
colloids	O
(	O
for	O
example	O
,	O
albumin	B-GP
,	O
fresh	O
frozen	O
plasma	O
)	O
as	O
adjuncts	O
has	O
been	O
successful	O
in	O
reducing	O
the	O
total	O
volume	O
[	O
12	O
].	O

Despite	O
extensive	O
research	O
into	O
resuscitation	O
fluid	O
compositions	O
and	O
volumes	O
,	O
little	O
is	O
known	O
about	O
the	O
effect	O
of	O
resuscitation	O
on	O
wound	O
healing	O
.	O

A	O
recent	O
meta	O
-	O
analysis	O
showed	O
a	O
positive	O
association	O
between	O
the	O
number	O
of	O
grafting	O
procedures	O
and	O
hypernatremia	B-DS
,	O
suggesting	O
that	O
high	O
serum	O
sodium	O
levels	O
may	O
inhibit	O
graft	O
take	O
[	O
103	O
].	O

Additionally	O
,	O
we	O
have	O
recently	O
shown	O
that	O
the	O
rate	O
of	O
wound	O
closure	O
(	O
healing	O
rate	O
)	O
is	O
significantly	O
faster	O
in	O
patients	O
who	O
received	O
lower	O
24	O
-	O
h	O
fluid	O
resuscitation	O
volumes	O
[	O
104	O
].	O

More	O
work	O
is	O
needed	O
to	O
evaluate	O
the	O
effect	O
of	O
resuscitation	O
on	O
wound	O
healing	O
trajectories	O
before	O
clinical	O
recommendations	O
for	O
preferred	O
fluid	O
compositions	O
and	O
volumes	O
can	O
be	O
made	O
.	O

Wound	O
coverage	O
and	O
grafting	O

Early	O
excision	O
and	O
grafting	O
has	O
been	O
the	O
standard	O
of	O
care	O
for	O
decades	O
.	O

Most	O
studies	O
have	O
shown	O
that	O
excision	O
within	O
24	O
to	O
48	O
h	O
after	O
injury	O
is	O
associated	O
with	O
decreased	O
blood	O
loss	O
,	O
infection	B-DS
,	O
length	O
of	O
hospital	O
stay	O
and	O
mortality	O
,	O
and	O
increased	O
graft	O
take	O
[	O
105	O
–	O
108	O
],	O
although	O
mortality	O
reductions	O
may	O
only	O
occur	O
in	O
patients	O
without	O
inhalation	O
injury	O
[	O
109	O
].	O

Since	O
one	O
of	O
the	O
main	O
challenges	O
in	O
treating	O
acute	O
thermal	O
injuries	O
is	O
preventing	O
infection	B-DS
,	O
excising	O
the	O
eschar	O
and	O
covering	O
the	O
wound	O
as	O
early	O
as	O
possible	O
are	O
critical	O
.	O

The	O
standard	O
for	O
rapid	O
and	O
permanent	O
closure	O
of	O
full	O
-	O
thickness	O
burns	O
is	O
a	O
split	O
-	O
thickness	O
skin	O
graft	O
from	O
an	O
uninjured	O
donor	O
site	O
on	O
the	O
same	O
patient	O
(	O
autograft	O
).	O

Such	O
grafting	O
provides	O
sufficient	O
coverage	O
without	O
risk	O
of	O
rejection	O
,	O
although	O
meta	O
-	O
analyses	O
have	O
yet	O
to	O
determine	O
the	O
failure	O
rate	O
of	O
split	O
-	O
thickness	O
skin	O
grafts	O
in	O
burn	O
patients	O
.	O

Split	O
-	O
thickness	O
skin	O
grafts	O
can	O
be	O
meshed	O
with	O
variable	O
expansion	O
ratios	O
to	O
increase	O
the	O
coverage	O
area	O
,	O
but	O
concerns	O
remain	O
over	O
the	O
effect	O
that	O
meshing	O
has	O
on	O
range	O
of	O
motion	O
[	O
110	O
]	O
and	O
the	O
graft	O
site	O
healing	O
rate	O
.	O

On	O
the	O
other	O
hand	O
,	O
donor	O
sites	O
are	O
painful	O
and	O
impose	O
their	O
own	O
wound	O
-	O
healing	O
burden	O
on	O
the	O
patient	O
[	O
111	O
].	O

Various	O
dressings	O
have	O
been	O
used	O
to	O
cover	O
donor	O
sites	O
during	O
healing	O
,	O
with	O
variable	O
results	O
[	O
112	O
].	O

Patients	O
with	O
more	O
extensive	O
burns	O
often	O
require	O
temporary	O
coverage	O
with	O
an	O
allograft	O
,	O
xenograft	O
,	O
skin	O
substitute	O
,	O
or	O
dermal	O
analog	O
due	O
to	O
insufficient	O
or	O
unavailable	O
donor	O
sites	O
.	O

Allografts	O
,	O
or	O
tissue	O
taken	O
from	O
a	O
living	O
or	O
deceased	O
human	B-OG
donor	O
,	O
and	O
xenografts	O
,	O
taken	O
from	O
a	O
different	O
species	O
,	O
promote	O
re	O
-	O
epithelialization	O
and	O
prepare	O
the	O
wound	O
bed	O
for	O
autograft	O
,	O
increasing	O
the	O
healing	O
rate	O
when	O
compared	O
with	O
traditional	O
dressings	O
[	O
113	O
].	O

A	O
recent	O
meta	O
-	O
analysis	O
suggested	O
that	O
since	O
allografts	O
and	O
xenografts	O
appear	O
to	O
be	O
equally	O
effective	O
,	O
xenografts	O
may	O
be	O
a	O
superior	O
choice	O
for	O
their	O
increased	O
safety	O
and	O
reduced	O
price	O
[	O
114	O
].	O

However	O
,	O
caution	O
should	O
be	O
exercised	O
in	O
drawing	O
broad	O
conclusions	O
from	O
this	O
meta	O
-	O
analysis	O
because	O
the	O
cited	O
studies	O
lack	O
standardization	O
and	O
critical	O
details	O
such	O
as	O
depth	O
and	O
size	O
of	O
burn	O
,	O
and	O
many	O
studies	O
cited	O
were	O
merely	O
anecdotal	O
.	O

A	O
cadaver	O
allograft	O
is	O
thus	O
widely	O
considered	O
the	O
best	O
material	O
for	O
temporary	O
closure	O
of	O
excised	O
wounds	O
in	O
patients	O
with	O
extensive	O
,	O
life	O
-	O
threatening	O
burns	O
and	O
inadequate	O
donor	O
sites	O
.	O

The	O
cadaver	O
allograft	O
is	O
also	O
the	O
preferred	O
material	O
for	O
protection	O
of	O
widely	O
meshed	O
autografts	O
(	O
3	O
:	O
1	O
or	O
higher	O
meshing	O
ratios	O
)	O
during	O
healing	O
.	O

In	O
the	O
latter	O
setting	O
,	O
the	O
allograft	O
is	O
applied	O
over	O
the	O
meshed	O
autograft	O
in	O
the	O
manner	O
of	O
a	O
sandwich	O
.	O

A	O
variety	O
of	O
different	O
skin	O
substitutes	O
and	O
dermal	O
analogs	O
exist	O
[	O
115	O
–	O
119	O
]	O
(	O
Table	O
2	O
)	O
that	O
can	O
be	O
broadly	O
divided	O
into	O
those	O
which	O
replace	O
the	O
epidermis	O
or	O
replace	O
the	O
dermis	O
[	O
120	O
,	O
121	O
].	O

Epidermal	O
substitutes	O
are	O
normally	O
only	O
a	O
few	O
cell	O
layers	O
thick	O
and	O
lack	O
normal	O
dermal	O
components	O
[	O
122	O
,	O
123	O
].	O

Commercially	O
available	O
dermal	O
substitutes	O
include	O
acellular	O
matrices	O
,	O
commonly	O
from	O
human	B-OG
–	O
for	O
example	O
,	O
Alloderm	O
(	O
LifeCell	O
,	O
Bridgewater	O
,	O
NJ	O
,	O
USA	O
)	O
or	O
GraftJacket	O
(	O
KCI	O
,	O
San	O
Antonio	O
,	O
TX	O
,	O
USA	O
)	O
–	O
or	O
other	O
sources	O
(	O
for	O
example	O
,	O
Integra	O
;	O
Integra	O
LifeSciences	O
,	O
Plainsboro	O
,	O
NJ	O
,	O
USA	O
).	O

Biobrane	O
(	O
Smith	O
&	O
Nephew	O
,	O
London	O
,	O
UK	O
)	O
is	O
a	O
semisynthetic	O
,	O
bilaminar	O
material	O
consisting	O
of	O
a	O
nylon	O
-	O
mesh	O
dermal	O
analog	O
(	O
bonded	O
with	O
porcine	O
collagen	B-GP
)	O
and	O
a	O
silicone	O
epidermal	O
analog	O
.	O

Biobrane	O
is	O
used	O
for	O
temporary	O
closure	O
of	O
superficial	O
burns	O
and	O
donor	O
sites	O
[	O
124	O
,	O
125	O
].	O

Products	O
currently	O
under	O
development	O
integrate	O
the	O
concept	O
of	O
dermal	O
scaffolds	O
that	O
actively	O
promote	O
revascularization	O
by	O
incorporating	O
stem	O
cells	O
and	O
growth	O
factors	O
to	O
recreate	O
a	O
favorable	O
cellular	O
microenvironment	O
[	O
126	O
,	O
127	O
].	O
Table	O
2Skin	O
substitutes	O
and	O
coverage	O
optionsProduct	O
nameClassificationCharacteristicsAvailability	O
(	O
company	O
)	O
EpiDexAutologousKeratinocyte	O
-	O
basedNo	O
(	O
Modex	O
,	O
Lausanne	O
,	O
Switzerland	O
)	O
AllodermAcellularHuman	O
originYes	O
(	O
LifeCell	O
,	O
Bridgewater	O
,	O
NJ	O
,	O
USA	O
)	O
Dermal	O
matrixGraftJacketAcellularHuman	O
originYes	O
(	O
KCI	O
,	O
San	O
Antonio	O
,	O
TX	O
,	O
USA	O
)	O
Tissue	O
scaffoldIntegraAcellularBovine	O
/	O
shark	O
originYes	O
(	O
Integra	O
,	O
Plainsboro	O
,	O
NJ	O
,	O
USA	O
)	O
Bilayer	O
matrixBiobraneAcellularBiocomposite	O
dressing	O
,	O
nylon	O
fibers	O
in	O
silicone	O
with	O
collagenYes	O
(	O
Smith	O
&	O
Nephew	O
,	O
London	O
,	O
UK	O
)	O
DermagraftCellularBioabsorbable	O
polyglactin	O
mesh	O
scaffold	O
with	O
human	B-OG
fibroblasts	O
(	O
neonatal	O
origin	O
)	O
Yes	O
(	O
Organogenesis	O
,	O
Canton	O
,	O
MA	O
,	O
USA	O
)	O
EpicelCellularKeratinocyte	O
-	O
based	O
cultured	O
epidermal	O
autograftYes	O
(	O
Genzyme	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
RecellCellularAutologous	O
cell	O
suspension	O
of	O
keratinocytes	O
,	O
fibroblasts	O
,	O
Langerhans	O
cells	O
and	O
melanocytesYes	O
(	O
Avita	O
,	O
Northridge	O
,	O
CA	O
,	O
USA	O
)	O
Sprayable	O
after	O
culture	O

Numerous	O
options	O
exist	O
for	O
dressings	O
[	O
128	O
,	O
129	O
].	O

The	O
selection	O
of	O
an	O
appropriate	O
dressing	O
depends	O
on	O
several	O
factors	O
,	O
including	O
depth	O
of	O
burn	O
,	O
condition	O
of	O
the	O
wound	O
bed	O
,	O
wound	O
location	O
,	O
desired	O
moisture	O
retention	O
and	O
drainage	O
,	O
required	O
frequency	O
of	O
dressing	O
changes	O
,	O
and	O
cost	O
.	O

While	O
many	O
factors	O
must	O
be	O
considered	O
in	O
dressing	O
selection	O
,	O
the	O
goals	O
in	O
selecting	O
the	O
most	O
appropriate	O
dressing	O
should	O
include	O
providing	O
protection	O
from	O
contamination	O
(	O
bacterial	O
or	O
otherwise	O
)	O
and	O
from	O
physical	O
damage	O
,	O
allowing	O
gas	O
exchange	O
and	O
moisture	O
retention	O
,	O
and	O
providing	O
comfort	O
to	O
enhance	O
functional	O
recovery	O
.	O

The	O
traditional	O
approach	O
to	O
burn	O
wound	O
care	O
developed	O
at	O
the	O
US	O
Army	O
Burn	O
Center	O
includes	O
alternation	O
of	O
mafenide	O
acetate	O
cream	O
in	O
the	O
morning	O
and	O
silver	O
sulfadiazine	O
cream	O
in	O
the	O
evening	O
,	O
with	O
gauze	O
dressings	O
used	O
over	O
the	O
creams	O
.	O

More	O
recently	O
,	O
silver	O
-	O
impregnated	O
and	O
other	O
dressings	O
have	O
been	O
introduced	O
.	O

Major	O
classes	O
of	O
dressings	O
include	O
:	O
alginate	O
,	O
for	O
example	O
Aquacel	O
(	O
ConvaTec	O
,	O
Bridgewater	O
,	O
NJ	O
,	O
USA	O
),	O
Comfeel	O
(	O
Coloplast	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
),	O
or	O
Sorbsan	O
(	O
Mylan	O
,	O
Morgantown	O
,	O
WV	O
,	O
USA	O
);	O
antimicrobial	O
,	O
for	O
example	O
Acticoat	O
(	O
Smith	O
&	O
Nephew	O
,	O
London	O
,	O
UK	O
)	O
or	O
Silverlon	O
(	O
Argentum	O
,	O
Geneva	O
,	O
IL	O
,	O
USA	O
);	O
collagen	B-GP
,	O
for	O
example	O
Fibracol	O
(	O
Johnson	O
&	O
Johnson	O
,	O
New	O
Brunswick	O
,	O
NJ	O
)	O
or	O
Puracol	O
(	O
Medline	O
,	O
Mundelein	O
,	O
IL	O
,	O
USA	O
);	O
hydrocolloid	O
,	O
for	O
example	O
Duoderm	O
(	O
ConvaTec	O
,	O
Bridgewater	O
,	O
NJ	O
,	O
USA	O
),	O
Granuflex	O
(	O
ConvaTec	O
,	O
Bridgewater	O
,	O
NJ	O
,	O
USA	O
),	O
or	O
Tegaderm	O
(	O
3M	O
,	O
Maplewood	O
,	O
MN	O
,	O
USA	O
);	O
hydrogel	O
,	O
for	O
example	O
Dermagel	O
(	O
Maximilian	O
Zenho	O
&	O
Co	O
,	O
Brussels	O
,	O
Belgium	O
),	O
SilvaSorb	O
(	O
Medline	O
,	O
Mundelein	O
,	O
IL	O
,	O
USA	O
),	O
or	O
Skintegrity	O
(	O
Medline	O
,	O
Mundelein	O
,	O
IL	O
,	O
USA	O
);	O
and	O
polyurethane	O
foam	O
,	O
for	O
example	O
Allevyn	O
(	O
Smith	O
&	O
Nephew	O
,	O
London	O
,	O
UK	O
)	O
or	O
Lyofoa	O
(	O
Molnycke	O
,	O
Gothenburg	O
,	O
Sweden	O
).	O

Notably	O
,	O
many	O
of	O
these	O
dressings	O
exhibit	O
antimicrobial	O
properties	O
through	O
silver	O
impregnation	O
,	O
but	O
recent	O
studies	O
suggest	O
silver	O
may	O
delay	O
wound	O
healing	O
and	O
should	O
not	O
be	O
routinely	O
used	O
on	O
uninfected	O
donor	O
skin	O
[	O
130	O
,	O
131	O
]	O
even	O
though	O
silver	O
dressings	O
may	O
reduce	O
wound	O
pain	O
[	O
132	O
].	O

In	O
patients	O
with	O
extensive	O
or	O
deep	O
burns	O
,	O
antimicrobial	O
efficacy	O
should	O
be	O
the	O
first	O
priority	O
in	O
burn	O
wound	O
care	O
.	O

Alternatively	O
,	O
cell	O
-	O
based	O
techniques	O
for	O
more	O
permanent	O
coverage	O
have	O
made	O
progress	O
.	O

Research	O
on	O
cultured	O
epithelial	O
cells	O
has	O
made	O
advancements	O
,	O
especially	O
with	O
respect	O
to	O
culture	O
time	O
.	O

Culture	O
-	O
based	O
options	O
,	O
such	O
as	O
Epicel	O
(	O
Genzyme	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
),	O
use	O
a	O
small	O
biopsy	O
of	O
the	O
patient	O
’	O
s	O
skin	O
to	O
provide	O
keratinocytes	O
,	O
which	O
are	O
expanded	O
over	O
2	O
to	O
3	O
weeks	O
(	O
for	O
Epicel	O
,	O
in	O
the	O
presence	O
of	O
proliferation	O
-	O
arrested	O
murine	O
fibroblasts	O
)	O
into	O
a	O
confluent	O
epidermal	O
autograft	O
.	O

Other	O
options	O
,	O
such	O
as	O
ReCell	O
(	O
Avita	O
,	O
Northridge	O
,	O
CA	O
,	O
USA	O
),	O
take	O
a	O
small	O
biopsy	O
of	O
the	O
patient	O
’	O
s	O
skin	O
and	O
prepare	O
a	O
mixture	O
of	O
keratinocytes	O
,	O
melanocytes	O
,	O
and	O
stem	O
cells	O
in	O
a	O
liquid	O
formulation	O
for	O
spraying	O
onto	O
the	O
excised	O
burn	O
wound	O
during	O
the	O
same	O
operation	O
[	O
133	O
–	O
135	O
].	O

These	O
techniques	O
may	O
reduce	O
the	O
amount	O
of	O
donor	O
skin	O
needed	O
for	O
treatment	O
of	O
large	O
burns	O
,	O
significantly	O
reducing	O
the	O
healing	O
time	O
of	O
both	O
the	O
donor	O
and	O
the	O
burn	O
sites	O
,	O
and	O
increasing	O
overall	O
graft	O
success	O
and	O
scar	O
quality	O
[	O
136	O
].	O

More	O
work	O
is	O
needed	O
on	O
cell	O
-	O
based	O
coverage	O
options	O
before	O
widespread	O
implementation	O
can	O
be	O
recommended	O
.	O

Keratinocytes	O
and	O
stem	O
cells	O

As	O
mentioned	O
previously	O
,	O
keratinocytes	O
play	O
a	O
vital	O
role	O
in	O
wound	O
closure	O
.	O

Cytokine	B-GP
activation	O
causes	O
keratinocyte	O
migration	O
in	O
the	O
proliferative	O
phase	O
,	O
leading	O
to	O
closure	O
and	O
restoration	O
of	O
a	O
vascular	O
network	O
[	O
35	O
].	O

Keratinocytes	O
can	O
also	O
be	O
activated	O
by	O
mu	B-GP
opioid	I-GP
receptor	I-GP
agonists	O
[	O
59	O
]	O
but	O
the	O
role	O
of	O
these	O
agonists	O
on	O
inflammation	O
and	O
wound	O
closure	O
remains	O
unclear	O
[	O
57	O
,	O
58	O
].	O

Despite	O
positive	O
studies	O
with	O
EpiDex	O
(	O
Modex	O
,	O
Lausanne	O
,	O
Switzerland	O
)	O
–	O
an	O
engineered	O
,	O
fully	O
differentiated	O
autologous	O
skin	O
substitute	O
derived	O
from	O
keratinocytes	O
showing	O
efficacy	O
comparable	O
with	O
split	O
-	O
thickness	O
skin	O
grafts	O
in	O
wound	O
closure	O
and	O
healing	O
[	O
137	O
]	O
–	O
results	O
have	O
yet	O
to	O
translate	O
into	O
clinically	O
viable	O
options	O
.	O

Studies	O
evaluating	O
expansion	O
of	O
keratinocytes	O
on	O
human	B-OG
fibroblasts	O
following	O
trypsin	B-GP
extraction	O
[	O
138	O
],	O
and	O
using	O
engineered	O
skin	O
with	O
keratinocytes	O
on	O
a	O
fibrin	B-GP
matrix	O
[	O
139	O
],	O
have	O
demonstrated	O
improvements	O
in	O
wound	O
healing	O
.	O

Retrospective	O
analyses	O
on	O
autologous	O
keratinocytes	O
showed	O
that	O
cultured	O
allogeneic	O
or	O
autologous	O
keratinocytes	O
may	O
accelerate	O
wound	O
healing	O
[	O
140	O
,	O
141	O
].	O

Taken	O
together	O
,	O
the	O
future	O
impact	O
of	O
keratinocyte	O
-	O
mediated	O
cell	O
coverage	O
options	O
is	O
promising	O
,	O
but	O
more	O
research	O
is	O
needed	O
[	O
134	O
].	O

Additionally	O
,	O
keratinocyte	O
-	O
based	O
treatments	O
should	O
be	O
pursued	O
carefully	O
,	O
as	O
overactivation	O
of	O
keratinocytes	O
can	O
contribute	O
to	O
the	O
development	O
of	O
hypertrophic	O
scarring	O
[	O
43	O
,	O
142	O
].	O

The	O
use	O
of	O
adult	O
stem	O
cells	O
,	O
including	O
bone	O
marrow	O
stem	O
cells	O
,	O
hair	O
follicle	O
stem	O
cells	O
,	O
and	O
adipose	O
stem	O
cells	O
,	O
in	O
acute	O
burn	O
care	O
is	O
an	O
exciting	O
topic	O
[	O
143	O
].	O

Addition	O
of	O
bone	O
marrow	O
stem	O
cells	O
to	O
nonhealing	O
chronic	O
wounds	O
leads	O
to	O
engraftment	O
of	O
cells	O
and	O
enhanced	O
wound	O
healing	O
[	O
144	O
,	O
145	O
].	O

Moreover	O
,	O
studies	O
have	O
reported	O
that	O
bone	O
marrow	O
stem	O
cells	O
can	O
transdifferentiate	O
towards	O
multiple	O
skin	O
cell	O
types	O
[	O
146	O
].	O

Mechanisms	O
of	O
action	O
of	O
bone	O
marrow	O
stem	O
cells	O
in	O
burns	O
are	O
not	O
fully	O
elucidated	O
,	O
but	O
modulation	O
of	O
inflammation	O
has	O
occurred	O
after	O
radiation	O
burns	O
in	O
humans	B-OG
[	O
147	O
].	O

Similarly	O
,	O
adipose	O
stem	O
cells	O
accelerate	O
re	O
-	O
epithelialization	O
by	O
paracrine	O
activation	O
of	O
host	O
cells	O
via	O
growth	O
factor	O
secretion	O
[	O
148	O
,	O
149	O
].	O

Also	O
,	O
hair	O
follicle	O
stem	O
cells	O
are	O
capable	O
of	O
generating	O
a	O
stratified	O
epidermis	O
on	O
human	B-OG
burn	O
wounds	O
[	O
150	O
].	O

Additionally	O
,	O
the	O
possibility	O
of	O
generating	O
a	O
cellular	O
skin	O
equivalent	O
is	O
being	O
explored	O
.	O

Hair	O
follicle	O
stem	O
cells	O
have	O
been	O
incorporated	O
into	O
products	O
,	O
such	O
as	O
Integra	O
,	O
to	O
investigate	O
wound	O
healing	O
[	O
151	O
].	O

A	O
cultured	O
skin	O
substitute	O
using	O
adipose	O
stem	O
cells	O
and	O
keratinocytes	O
has	O
been	O
developed	O
that	O
produces	O
epidermal	O
,	O
dermal	O
,	O
and	O
hypodermal	O
stratification	O
[	O
152	O
].	O

Moreover	O
,	O
human	B-OG
adipose	O
stem	O
cells	O
that	O
would	O
normally	O
be	O
discarded	O
have	O
recently	O
been	O
isolated	O
from	O
debrided	O
burn	O
eschar	O
tissue	O
[	O
153	O
]	O
and	O
used	O
to	O
generate	O
a	O
tri	O
-	O
layered	O
,	O
vascularized	O
construct	O
[	O
154	O
].	O

Promising	O
data	O
with	O
nonembryonic	O
stems	O
cells	O
such	O
as	O
these	O
have	O
stimulated	O
interest	O
into	O
future	O
applications	O
and	O
development	O
,	O
and	O
undoubtedly	O
further	O
investigations	O
will	O
produce	O
exciting	O
results	O
.	O

Other	O
considerations	O
and	O
future	O
directions	O

Monitoring	O
and	O
predicting	O
wound	O
healing	O

No	O
new	O
skin	O
-	O
based	O
technology	O
can	O
substitute	O
for	O
careful	O
attention	O
by	O
the	O
burn	O
team	O
to	O
the	O
progress	O
(	O
or	O
lack	O
thereof	O
)	O
of	O
wound	O
healing	O
.	O

The	O
WoundFlow	O
computer	O
software	O
program	O
was	O
developed	O
as	O
an	O
enhancement	O
over	O
the	O
traditional	O
paper	O
Lund	O
–	O
Browder	O
diagram	O
to	O
more	O
accurately	O
quantify	O
and	O
track	O
burn	O
injuries	O
over	O
time	O
[	O
104	O
,	O
155	O
].	O

WoundFlow	O
is	O
an	O
electronic	O
mapping	O
program	O
that	O
calculates	O
burn	O
size	O
and	O
tracks	O
wound	O
healing	O
[	O
104	O
,	O
155	O
].	O

The	O
ability	O
to	O
accurately	O
track	O
burn	O
wound	O
healing	O
over	O
time	O
will	O
support	O
both	O
clinical	O
care	O
and	O
future	O
studies	O
that	O
compare	O
healing	O
rates	O
and	O
outcomes	O
following	O
different	O
treatments	O
.	O

Notably	O
,	O
this	O
study	O
demonstrated	O
that	O
delayed	O
wound	O
healing	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
risk	O
of	O
mortality	O
[	O
104	O
,	O
155	O
].	O

The	O
ability	O
to	O
predict	O
whether	O
a	O
burn	O
wound	O
will	O
spontaneously	O
heal	O
or	O
not	O
would	O
greatly	O
improve	O
patient	O
care	O
.	O

Furthermore	O
,	O
the	O
ability	O
to	O
uniquely	O
tailor	O
treatment	O
to	O
each	O
individual	O
patient	O
would	O
improve	O
patient	O
outcomes	O
and	O
decrease	O
the	O
time	O
to	O
functional	O
recovery	O
,	O
reducing	O
the	O
overall	O
cost	O
of	O
care	O
.	O

Biomarkers	O
may	O
provide	O
a	O
means	O
to	O
allow	O
for	O
tailored	O
treatments	O
and	O
to	O
give	O
insight	O
into	O
wound	O
healing	O
mechanisms	O
[	O
156	O
–	O
161	O
].	O

Significant	O
efforts	O
in	O
the	O
search	O
for	O
predictive	O
biomarkers	O
for	O
wound	O
failure	O
have	O
determined	O
that	O
serum	O
cytokines	B-GP
,	O
such	O
as	O
interleukin	B-GP
-	I-GP
3	I-GP
and	O
12p70	O
,	O
and	O
serum	O
procalcitonin	B-GP
are	O
independently	O
associated	O
with	O
wound	O
failure	O
[	O
161	O
].	O

Additional	O
candidates	O
have	O
been	O
identified	O
[	O
158	O
–	O
160	O
]	O
but	O
further	O
work	O
is	O
needed	O
to	O
model	O
complex	O
,	O
temporal	O
serum	O
cytokine	B-GP
profiles	O
into	O
an	O
effective	O
predictor	O
for	O
wound	O
healing	O
.	O

In	O
addition	O
to	O
evaluating	O
serum	O
cytokine	B-GP
profiles	O
,	O
candidate	O
biomarkers	O
have	O
been	O
identified	O
in	O
wound	O
effluent	O
[	O
161	O
],	O
which	O
may	O
be	O
a	O
better	O
medium	O
for	O
predicting	O
local	O
wound	O
healing	O
than	O
cytokines	B-GP
in	O
the	O
circulation	O
[	O
162	O
].	O

Wound	O
exudate	O
has	O
been	O
shown	O
to	O
contain	O
elevated	O
levels	O
of	O
immunosuppressive	O
and	O
proinflammatory	B-GP
cytokines	I-GP
,	O
such	O
as	O
interleukin	B-GP
-	I-GP
1β	I-GP
,	O
interleukin	B-GP
-	I-GP
2	I-GP
,	O
interleukin	B-GP
-	I-GP
6	I-GP
,	O
and	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
alpha	I-GP
[	O
163	O
].	O

In	O
fact	O
,	O
dipeptidyl	B-GP
peptidase	I-GP
IV	I-GP
and	O
aminopeptidase	B-GP
have	O
been	O
identified	O
in	O
burn	O
wound	O
exudate	O
with	O
a	O
significantly	O
different	O
ratio	O
from	O
that	O
found	O
in	O
plasma	O
[	O
164	O
].	O

Other	O
work	O
on	O
local	O
wound	O
biomarkers	O
using	O
biopsies	O
has	O
shown	O
that	O
a	O
host	O
of	O
proteins	O
are	O
upregulated	O
during	O
wound	O
healing	O
[	O
165	O
].	O

More	O
work	O
is	O
needed	O
to	O
establish	O
a	O
biomarker	O
profile	O
that	O
can	O
accurately	O
predict	O
wound	O
healing	O
and	O
to	O
identify	O
potential	O
novel	O
areas	O
for	O
therapeutic	O
intervention	O
.	O

In	O
addition	O
to	O
examining	O
burn	O
wounds	O
directly	O
,	O
and	O
the	O
wound	O
exudate	O
,	O
another	O
potential	O
method	O
for	O
examining	O
the	O
ability	O
of	O
burn	O
wounds	O
to	O
heal	O
is	O
non	O
-	O
invasive	O
imaging	O
[	O
166	O
].	O

To	O
this	O
end	O
,	O
a	O
number	O
of	O
non	O
-	O
invasive	O
imaging	O
techniques	O
have	O
been	O
investigated	O
for	O
their	O
use	O
in	O
determining	O
burn	O
depth	O
.	O

Such	O
techniques	O
include	O
terahertz	O
imaging	O
,	O
spatial	O
-	O
frequency	O
-	O
domain	O
imaging	O
,	O
near	O
-	O
infrared	O
spectroscopic	O
imaging	O
,	O
and	O
reflectance	O
-	O
mode	O
confocal	O
microscopy	O
,	O
among	O
others	O
[	O
167	O
–	O
172	O
].	O

While	O
many	O
of	O
these	O
techniques	O
have	O
not	O
yet	O
been	O
refined	O
sufficiently	O
for	O
clinical	O
application	O
,	O
the	O
most	O
successful	O
research	O
efforts	O
into	O
imaging	O
techniques	O
for	O
burn	O
wounds	O
examine	O
blood	O
flow	O
,	O
such	O
as	O
laser	O
Doppler	O
imaging	O
and	O
indocyanine	O
green	O
angiography	O
[	O
173	O
].	O

Laser	O
Doppler	O
imaging	O
provides	O
the	O
most	O
evidence	O
for	O
accurately	O
assessing	O
burn	O
severity	O
[	O
174	O
],	O
but	O
it	O
has	O
been	O
shown	O
that	O
laser	O
Doppler	O
imaging	O
is	O
only	O
superior	O
to	O
visual	O
assessment	O
48	O
h	O
after	O
thermal	O
injury	O
[	O
175	O
].	O

Additional	O
studies	O
are	O
needed	O
to	O
fully	O
explore	O
the	O
potential	O
for	O
incorporation	O
of	O
non	O
-	O
invasive	O
imaging	O
modalities	O
into	O
the	O
routine	O
treatment	O
of	O
burn	O
wounds	O
.	O

Obese	O
patients	O

As	O
the	O
obese	O
population	O
continues	O
to	O
grow	O
[	O
176	O
],	O
new	O
treatment	O
approaches	O
will	O
be	O
required	O
.	O

Obese	O
burn	O
patients	O
present	O
with	O
a	O
variety	O
of	O
unique	O
characteristics	O
that	O
include	O
:	O
increased	O
rates	O
of	O
diabetes	B-DS
,	O
hypertension	B-DS
,	O
cardiac	B-DS
disease	I-DS
,	O
and	O
pulmonary	B-DS
disease	I-DS
;	O
altered	O
pharmacokinetics	O
and	O
pharmacodynamics	O
;	O
and	O
altered	O
immune	O
responses	O
[	O
177	O
].	O

Even	O
the	O
commonly	O
used	O
Lund	O
–	O
Browder	O
chart	O
for	O
estimation	O
of	O
TBSA	O
is	O
problematic	O
for	O
obese	O
patients	O
because	O
it	O
fails	O
to	O
account	O
for	O
altered	O
body	O
-	O
mass	O
distribution	O
in	O
these	O
patients	O
[	O
178	O
].	O

Hence	O
,	O
analysis	O
of	O
group	O
differences	O
and	O
controlled	O
clinical	O
studies	O
in	O
unique	O
patient	O
populations	O
are	O
needed	O
[	O
179	O
].	O

Older	O
patients	O

Census	O
predictions	O
suggest	O
that	O
the	O
older	O
population	O
will	O
double	O
in	O
the	O
next	O
20	O
years	O
.	O

Since	O
older	O
people	O
are	O
at	O
increased	O
risk	O
for	O
burn	O
injury	O
,	O
an	O
increasing	O
number	O
of	O
burn	O
injuries	O
among	O
the	O
older	O
population	O
should	O
be	O
expected	O
.	O

A	O
recent	O
review	O
delineated	O
the	O
unique	O
burn	O
pathophysiology	O
,	O
comorbidities	O
,	O
and	O
treatment	O
strategies	O
for	O
the	O
older	O
population	O
[	O
180	O
].	O

Detailing	O
all	O
of	O
the	O
unique	O
considerations	O
for	O
the	O
older	O
burn	O
population	O
is	O
outside	O
the	O
scope	O
of	O
this	O
review	O
,	O
but	O
several	O
key	O
points	O
are	O
noteworthy	O
.	O

Most	O
burns	O
among	O
older	O
people	O
occur	O
at	O
home	O
,	O
especially	O
in	O
the	O
kitchen	O
and	O
bathroom	O
,	O
due	O
to	O
diminished	O
alertness	O
,	O
slower	O
reaction	O
time	O
,	O
and	O
reduced	O
mobility	O
[	O
181	O
].	O

Reductions	O
in	O
metabolic	O
rate	O
and	O
skin	O
thickness	O
with	O
age	O
result	O
in	O
more	O
severe	O
burns	O
,	O
and	O
more	O
extensive	O
full	O
-	O
thickness	O
burns	O
are	O
associated	O
with	O
increased	O
mortality	O
[	O
182	O
].	O

Comorbidities	O
such	O
as	O
diabetes	B-DS
and	O
cardiovascular	B-DS
disease	I-DS
complicate	O
treatment	O
,	O
and	O
may	O
exacerbate	O
the	O
postburn	O
hypermetabolic	O
response	O
[	O
183	O
].	O

Several	O
formulas	O
for	O
predicting	O
the	O
survival	O
of	O
older	O
patients	O
,	O
such	O
as	O
the	O
Baux	O
score	O
[	O
184	O
],	O
have	O
received	O
wide	O
acceptance	O
and	O
can	O
help	O
guide	O
clinicians	O
in	O
patient	O
treatment	O
.	O

Unique	O
treatment	O
considerations	O
for	O
older	O
patients	O
should	O
include	O
attentive	O
resuscitation	O
to	O
reduce	O
the	O
risk	O
of	O
volume	O
overload	O
,	O
judicious	O
ventilator	O
support	O
,	O
careful	O
analgesic	O
administration	O
,	O
prudently	O
timed	O
excision	O
and	O
grafting	O
,	O
and	O
extended	O
rehabilitation	O
for	O
functional	O
recovery	O
[	O
180	O
].	O

The	O
older	O
population	O
presents	O
a	O
unique	O
challenge	O
to	O
the	O
burn	O
clinician	O
,	O
and	O
the	O
treatment	O
of	O
patients	O
must	O
be	O
carefully	O
considered	O
on	O
a	O
case	O
-	O
by	O
-	O
case	O
basis	O
.	O

Future	O
directions	O

Adult	O
burn	O
patients	O
with	O
increased	O
markers	O
of	O
inflammatory	O
stress	O
exhibit	O
reduced	O
serum	O
levels	O
of	O
vitamin	O
A	O
despite	O
normal	O
markers	O
of	O
oxidative	O
stress	O
[	O
185	O
–	O
187	O
].	O

Additionally	O
,	O
limited	O
preclinical	O
studies	O
show	O
that	O
polyprenoic	O
acid	O
and	O
retinol	O
can	O
facilitate	O
wound	O
healing	O
[	O
188	O
],	O
and	O
that	O
retinoids	O
are	O
efficacious	O
on	O
a	O
variety	O
of	O
other	O
skin	B-DS
conditions	I-DS
[	O
189	O
].	O

Moreover	O
,	O
early	O
clinical	O
studies	O
have	O
shown	O
that	O
retinoid	O
treatment	O
effectively	O
increases	O
scar	O
elasticity	O
[	O
190	O
,	O
191	O
].	O

Taken	O
together	O
,	O
these	O
data	O
highlight	O
the	O
need	O
for	O
studies	O
evaluating	O
retinoids	O
on	O
burn	O
wound	O
healing	O
outcomes	O
.	O

Pirfenidone	O
was	O
originally	O
developed	O
as	O
an	O
antihelminthic	O
and	O
antipyretic	O
agent	O
,	O
but	O
recent	O
work	O
has	O
demonstrated	O
that	O
it	O
also	O
has	O
anti	O
-	O
inflammatory	O
,	O
antioxidative	O
,	O
and	O
antiproliferative	O
effects	O
[	O
192	O
].	O

In	O
particular	O
,	O
the	O
antifibrotic	O
properties	O
of	O
pirfenidone	O
attenuate	O
fibroblast	O
proliferation	O
and	O
collagen	B-GP
deposition	O
in	O
vitro	O
and	O
in	O
preclinical	O
models	O
[	O
192	O
].	O

Pirfenidone	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
in	O
Europe	O
,	O
Japan	O
,	O
and	O
the	O
USA	O
.	O

The	O
antifibrotic	O
actions	O
of	O
pirfenidone	O
and	O
other	O
data	O
suggest	O
that	O
pirfenidone	O
could	O
modulate	O
the	O
tissue	O
response	O
to	O
injury	O
at	O
multiple	O
stages	O
of	O
wound	O
repair	O
to	O
improve	O
scarring	O
and	O
function	O
as	O
an	O
adjuvant	O
for	O
abnormal	O
wound	O
healing	O
processes	O
.	O

Preclinical	O
investigations	O
are	O
currently	O
underway	O
in	O
rabbits	B-OG
[	O
193	O
,	O
194	O
]	O
and	O
rats	B-OG
[	O
195	O
],	O
but	O
controlled	O
clinical	O
studies	O
are	O
needed	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
pirfenidone	O
on	O
abnormal	O
wound	O
healing	O
.	O

The	O
treatment	O
of	O
burn	O
wounds	O
with	O
hyperbaric	O
oxygen	O
was	O
first	O
investigated	O
in	O
the	O
mid	O
-	O
1960s	O
and	O
garnered	O
some	O
attention	O
in	O
the	O
decades	O
following	O
,	O
but	O
controversy	O
remains	O
over	O
potential	O
risks	O
and	O
costs	O
[	O
196	O
,	O
197	O
].	O

Recent	O
work	O
in	O
rat	B-OG
models	O
has	O
shown	O
that	O
hyperbaric	O
oxygen	O
reduces	O
healing	O
time	O
and	O
improves	O
scar	O
appearance	O
of	O
burn	O
injuries	O
[	O
198	O
].	O

Advancements	O
in	O
hyperbaric	O
chambers	O
have	O
reduced	O
the	O
overall	O
cost	O
associated	O
with	O
treatment	O
,	O
and	O
controlled	O
clinical	O
trials	O
in	O
humans	B-OG
are	O
beginning	O
to	O
produce	O
data	O
supporting	O
the	O
conclusion	O
that	O
hyperbaric	O
oxygen	O
is	O
safe	O
and	O
effective	O
for	O
improving	O
burn	O
wound	O
healing	O
[	O
199	O
–	O
201	O
].	O

However	O
,	O
more	O
data	O
are	O
needed	O
before	O
broad	O
conclusions	O
can	O
be	O
made	O
about	O
the	O
overall	O
utility	O
of	O
hyperbaric	O
oxygen	O
for	O
treating	O
burns	O
.	O

Future	O
research	O
on	O
burn	O
patient	O
care	O
will	O
focus	O
on	O
a	O
variety	O
of	O
areas	O
[	O
202	O
].	O

Considering	O
a	O
current	O
survival	O
rate	O
of	O
over	O
97	O
%	O
for	O
burn	O
patients	O
[	O
3	O
],	O
major	O
advancements	O
from	O
the	O
past	O
several	O
decades	O
have	O
improved	O
patient	O
care	O
such	O
that	O
significant	O
future	O
improvements	O
in	O
patient	O
survival	O
rate	O
will	O
be	O
more	O
difficult	O
.	O

However	O
,	O
improvements	O
are	O
still	O
needed	O
in	O
individualized	O
care	O
,	O
namely	O
prediction	O
of	O
patient	O
outcomes	O
and	O
the	O
ability	O
to	O
tailor	O
treatment	O
to	O
optimize	O
functional	O
recovery	O
.	O

Improvements	O
are	O
also	O
needed	O
to	O
accelerate	O
wound	O
closure	O
and	O
healing	O
and	O
to	O
improve	O
psychological	O
care	O
to	O
promote	O
successful	O
reintegration	O
.	O

Research	O
in	O
inflammation	O
,	O
infection	B-DS
,	O
stem	O
cells	O
,	O
grafting	O
,	O
biomarkers	O
,	O
inflammation	O
control	O
,	O
and	O
rehabilitation	O
will	O
continue	O
to	O
improve	O
individualized	O
care	O
and	O
create	O
new	O
treatment	O
options	O
.	O

Conclusion	O

The	O
various	O
clinical	O
challenges	O
in	O
treating	O
acute	O
thermal	O
injuries	O
include	O
balancing	O
the	O
many	O
factors	O
that	O
affect	O
wound	O
healing	O
to	O
reduce	O
the	O
length	O
of	O
stay	O
(	O
and	O
associated	O
cost	O
of	O
treatment	O
),	O
the	O
risk	O
of	O
infection	B-DS
,	O
the	O
time	O
to	O
wound	O
closure	O
,	O
and	O
the	O
overall	O
time	O
to	O
functional	O
recovery	O
.	O

The	O
treatment	O
of	O
burn	O
wounds	O
has	O
evolved	O
over	O
several	O
decades	O
through	O
clinical	O
and	O
preclinical	O
research	O
.	O

Significant	O
advancements	O
have	O
been	O
made	O
in	O
patient	O
care	O
,	O
including	O
tracking	O
wound	O
healing	O
,	O
developing	O
novel	O
graft	O
and	O
coverage	O
options	O
,	O
controlling	O
inflammation	O
,	O
optimizing	O
dietary	O
needs	O
,	O
and	O
testing	O
unique	O
pharmacological	O
interventions	O
.	O

As	O
a	O
result	O
of	O
these	O
efforts	O
,	O
patient	O
survival	O
has	O
improved	O
along	O
with	O
a	O
concomitant	O
decrease	O
in	O
the	O
length	O
of	O
stay	O
,	O
which	O
in	O
turn	O
results	O
in	O
a	O
decreased	O
cost	O
to	O
the	O
patient	O
and	O
the	O
medical	O
providers	O
.	O

A	O
summary	O
of	O
selected	O
clinical	O
recommendations	O
is	O
provided	O
(	O
Table	O
3	O
)	O
to	O
aid	O
the	O
intensivist	O
,	O
but	O
it	O
is	O
important	O
to	O
remember	O
that	O
burn	O
patients	O
present	O
unique	O
challenges	O
based	O
on	O
multiple	O
variables	O
(	O
for	O
example	O
,	O
age	O
,	O
TBSA	O
,	O
comorbidities	O
)	O
and	O
treatment	O
decisions	O
must	O
be	O
tailored	O
to	O
each	O
patient	O
’	O
s	O
needs	O
.	O

Current	O
and	O
future	O
research	O
will	O
continue	O
to	O
identify	O
novel	O
targets	O
and	O
treatment	O
paradigms	O
to	O
further	O
improve	O
burn	O
wound	O
care	O
.	O
Table	O
3Recommendations	O
for	O
the	O
intensivistAccurate	O
measurement	O
of	O
burn	O
size	O
using	O
a	O
Lund	O
–	O
Browder	O
chartCarefully	O
titrated	O
fluid	O
resuscitation	O
,	O
to	O
balance	O
risks	O
of	O
edema	O
formation	O
with	O
those	O
of	O
ongoing	O
hypoperfusionEarly	O
initiation	O
of	O
effective	O
topical	O
antimicrobial	O
therapy	O
(	O
mafenide	O
acetate	O
or	O
silver	O
-	O
based	O
creams	O
/	O
dressings	O
)	O
Daily	O
inspection	O
of	O
the	O
wounds	O
by	O
a	O
qualified	O
surgeon	O
or	O
wound	O
care	O
expertEarly	O
excision	O
and	O
grafting	O
of	O
all	O
full	O
thickness	O
and	O
deep	O
partial	O
thickness	O
burnsAggressive	O
treatment	O
of	O
infected	O
wounds	O
(	O
resuscitate	O
,	O
broad	O
-	O
spectrum	O
topical	O
and	O
systemic	O
antimicrobials	O
,	O
excision	O
,	O
or	O
re	O
-	O
excision	O
)	O
Rehabilitation	O
in	O
the	O
ICU	O
to	O
minimize	O
the	O
functional	O
consequences	O
of	O
prolonged	O
immobilization	O
and	O
contracture	O
formation	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

